Brian Doyle

CLSA analysts Caroline Levy and Brian Doyle think Anheuser Busch Inbev SA (ADR) (NYSE: BUD) has almost completed all acquisition approval hurdles. The brokerage maintains its Outperform rating and $142 price target on the shares of the company. The analysts pointed out that Anheuser Busch received...

Sugary drinks are not only bad for your health, they may also be bad for your investment portfolio. CLSA analyst Brian Doyle recently spoke with endocrinology and obesity expert Dr. Robert Lustig about the food industry’s long-term impact on the health of consumers. Dr. Lustig, who is a...